Doxorubicin: nanotechnological overviews from bench to bedside.

Doxorubicin (DOX) is considered one of the most effective chemotherapeutic agents, used as a first-line drug in numerous types of cancer. Nevertheless, it exhibits serious adverse effects, such as lethal cardiotoxicity and dose-limiting myelosuppression. In this review, we focus on the description and the clinical benefits of different DOX-loaded nanotechnological platforms, not only those commercially available but also the ones that are currently in clinical phases, such as liposomes, polymeric nanoparticles, polymer-drug conjugates, polymeric micelles and ligand-based DOX-loaded nanoformulations. Although some DOX-based nanoproducts are currently being used in the clinical field, it is clear that further research is necessary to achieve improvements in cancer therapeutics.

• Publication year

  2017

• Venue

  Drug Discovery Today

• Publication date

  2017-02-01

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.1016/j.drudis.2016.11.005PMID 27890669
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New signal transduction paradigms in anthracycline-induced cardiotoxicity.

  2016cited by this paper
• Abstract 2143: Mechanistic study of the relative cytotoxicity of doxorubicin loaded nanoparticle formulation compared to free doxorubicin in hepatocellular carcinoma (HCC) cell lines

  2016cited by this paper
• pH-sensitive micelles based on acid-labile pluronic F68-curcumin conjugates for improved tumor intracellular drug delivery.

  2016cited by this paper
• Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs.

  2016cited by this paper
• Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics

  2015cited by this paper
• Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model

  2015cited by this paper
• A tale of the two PEGylated liposomal doxorubicins

  2015cited by this paper
• Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study

  2015cited by this paper
• Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects

  2015cited by this paper
• Progress of drug-loaded polymeric micelles into clinical studies.

  2014cited by this paper
• Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation.

  2014cited by this paper
• Nanoparticle aggregation: principles and modeling.

  2014cited by this paper
• Magnetic resonance imaging-visible and pH-sensitive polymeric micelles for tumor targeted drug delivery.

  2014cited by this paper
• Development of liposomal formulations: From concept to clinical investigations

  2013cited by this paper
• Nanocarriers for intravenous injection--the long hard road to the market.

  2013cited by this paper
• Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx

  2013cited by this paper
• A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

  2013cited by this paper
• Liposome: classification, preparation, and applications

  2013cited by this paper
• Therapeutic nanoparticles in clinics and under clinical evaluation.

  2013cited by this paper
• The European Commission's recommendation on the definition of nanomaterial makes an impact

  2012cited by this paper
• Doxil®--the first FDA-approved nano-drug: lessons learned.

  2012cited by this paper
• Nanoparticle delivery of cancer drugs.

  2012cited by this paper
• The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.

  2011cited by this paper
• Industry Update: The latest developments in therapeutic delivery.

  2011cited by this paper
• Clinical Developments in Nanotechnology for Cancer Therapy

  2011cited by this paper
• Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.

  2011cited by this paper
• Doxorubicin pathways: pharmacodynamics and adverse effects

  2011cited by this paper
• Natural glycoconjugates with antitumor activity.

  2011cited by this paper
• A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

  2011cited by this paper
• Biotechnological doxorubicin production: pathway and regulation engineering of strains for enhanced production

  2010cited by this paper
• A complementary definition of nanomaterial

  2010cited by this paper
• Isolation and genetic manipulation of the antibiotic down-regulatory gene, wblA ortholog for doxorubicin-producing Streptomyces strain improvement

  2010cited by this paper
• Self-resistance mechanism in Streptomyces peucetius: overexpression of drrA, drrB and drrC for doxorubicin enhancement.

  2010cited by this paper
• Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking.

  2010cited by this paper
• Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer.

  2009cited by this paper
• Doxorubicin-Induced Cardiac Toxicity and Cardiac Rest Gated Blood Pool Imaging

  2009cited by this paper
• Enhancement of doxorubicin production by expression of structural sugar biosynthesis and glycosyltransferase genes in Streptomyces peucetius.

  2009cited by this paper
• Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.

  2009cited by this paper
• Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum.

  2009cited by this paper
• Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).

  2009cited by this paper
• Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer

  2009cited by this paper
• Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.

  2008cited by this paper
• Pharmacokinetics and biodistribution of nanoparticles.

  2008cited by this paper
• Anticancer Polymeric Nanomedicines

  2007cited by this paper
• Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation

  2007cited by this paper
• Functionalized Micellar Systems for Cancer Targeted Drug Delivery

  2007cited by this paper
• Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticles

  2007cited by this paper
• Solitary colorectal liver metastasis: resection determines outcome.

  2006cited by this paper
• Micellar Nanocarriers: Pharmaceutical Perspectives

  2006cited by this paper
• Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma

  2006cited by this paper
• The liposomal formulation of doxorubicin.

  2005cited by this paper
• Local Recurrence After Hepatic Radiofrequency Coagulation: Multivariate Meta-Analysis and Review of Contributing Factors

  2005cited by this paper
• Identification and characterization of the afsR homologue regulatory gene from Streptomyces peucetius ATCC 27952.

  2005cited by this paper
• Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties

  2005cited by this paper
• Role of nanotechnology in targeted drug delivery and imaging: a concise review.

  2005cited by this paper
• Role of pegylated liposomal doxorubicin in ovarian cancer.

  2005cited by this paper
• Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.

  2004cited by this paper
• Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

  2004cited by this paper
• Time dependency of adriamycin and adriamycinol kinetics

  2004cited by this paper
• Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer.

  2004cited by this paper
• Use of liposomal anthracyclines in Kaposi's sarcoma.

  2004cited by this paper
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

  2004cited by this paper
• Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer

  2004cited by this paper
• Polymeric micelles for delivery of poorly water-soluble compounds.

  2003cited by this paper
• Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.

  2002cited by this paper
• Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

  2002cited by this paper
• PEG-based micelles as carriers of contrast agents for different imaging modalities.

  2002cited by this paper
• Ligand-targeted therapeutics in anticancer therapy

  2002cited by this paper
• Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy.

  2002cited by this paper
• Liposomes: Applications in Medicine

  2001cited by this paper
• Enzymes inside lipid vesicles: preparation, reactivity and applications.

  2001cited by this paper
• Ultrasound-guided radiofrequency thermal ablation of liver tumors: Percutaneous, laparoscopic, and open surgical approaches

  2001cited by this paper
• Development of the polymer micelle carrier system for doxorubicin.

  2001cited by this paper
• Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

  2001cited by this paper
• Phase I and pharmacokinetic study of a stable, polyethylene‐glycolated liposomal doxorubicin in patients with solid tumors

  2001cited by this paper
• Structure and design of polymeric surfactant-based drug delivery systems.

  2001cited by this paper
• Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.

  1999cited by this paper
• How Fe3+ binds anthracycline antitumour compounds. The myth and the reality of a chemical sphinx.

  1999cited by this paper
• Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

  1999cited by this paper
• A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.

  1999cited by this paper
• Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

  1998cited by this paper
• Circular dichroism studies on anthracycline antitumor compounds. Relationship between the molecular structure and the spectroscopic data.

  1998cited by this paper
• Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group.

  1998cited by this paper
• The Streptomyces peucetius dpsY anddnrX Genes Govern Early and Late Steps of Daunorubicin and Doxorubicin Biosynthesis

  1998cited by this paper
• Liposomes preparation methods.

  1996cited by this paper
• Enhanced antibiotic production by manipulation of the Streptomyces peucetius dnrH and dnmT genes involved in doxorubicin (adriamycin) biosynthesis

  1996cited by this paper
• Recent advances in liposomal drug-delivery systems.

  1995cited by this paper
• Drug targeting with nanoparticles

  1994cited by this paper
• Anthracycline antitumour agents

  1986cited by this paper
• Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.

  1986cited by this paper
• Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.

  1985cited by this paper
• Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II.

  1984cited by this paper
• Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

  1983cited by this paper
• The discovery of daunorubicin.

  1981cited by this paper
• Liposomes as drug carriers.

  1977cited by this paper
• Intravenous Medications: A Handbook for Nurses and Allied Health Professionals

  1977cited by this paper
• Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius

  1969cited by this paper
• Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia

  1967cited by this paper
• Diffusion of univalent ions across the lamellae of swollen phospholipids.

  1965cited by this paper

• Next Generation Calcium Nanomaterials: Disrupting Tumor Ca2⁺ Homeostasis for Enhanced Cancer Therapy.

  2026cites this paper
• Allosteric DNA Nanorobots for Targeted Glioma Therapy: Acid‐Triggered Doxorubicin Delivery

  2026cites this paper
• Electrospun fibrous membrane with triple synergistic effects for cancer therapy.

  2026cites this paper
• Integrating network toxicology, machine learning, and molecular dynamics simulations to reveal tanshinone iia’s dual mechanisms in TNBC and doxorubicin-induced cardiotoxicity

  2026cites this paper
• Cyclodextrin-based nanocarriers as promising scaffolds for overcoming challenges of doxorubicin delivery in cancer chemotherapy

  2025cites this paper
• In vivo and in situ monitoring of doxorubicin pharmacokinetics with an implantable bioresorbable optical sensor

  2025cites this paper
• A Comprehensive Analysis of Natural Bioactive Molecules for the Treatment and Control of Glioblastoma Multiforme (GBM) Targeting Underlying Molecular Mechanism

  2025cites this paper
• Doxorubicin and NFL-TBS.40-63 peptide loaded gold nanoparticles as a multimodal therapy of glioblastoma

  2025cites this paper
• Sigma receptors and mitochondria-associated ER membranes are converging therapeutic targets for Alzheimer’s disease

  2025influential citation
• Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy—Differences in Cardiotoxicity

  2025cites this paper
• Topoisomerase II-targeting anticancer clinical candidates and drugs: A critical analysis, unravelling molecular medicinal insights and promising research roadmap.

  2025cites this paper
• Synergistic chemo-photothermal therapy using doxorubicin-loaded gold nanorods for enhanced apoptosis in lung cancer cells

  2025cites this paper
• Periodate-Mediated Cross-Linking for the Preparation of Catechol Conjugated Albumin Nanoparticles Used for in Vitro Drug Delivery

  2025cites this paper
• Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence

  2025cites this paper
• Biodegradable Cu-based sonozymes for tumor-specific cuproptosis-enhanced sono-immunotherapy through activating cGAS-STING pathway and sensitizing immune checkpoint blockade

  2025cites this paper
• Identification of Potential Molecular Targets of Doxorubicin for Application in Skin Cancer: A Network Pharmacology and Molecular Docking Perspective.

  2025cites this paper
• Induction of oxidative stress and functional impairment by Doxorubicin in rat salivary glands.

  2025cites this paper
• Development of a Potential Multilayered Biofunctional Dressing for Localized Postoperative Cancer Treatment: A Hybrid Approach Using 3D Printing and Electrospinning

  2025cites this paper
• Development of a liposomal formulation of a TKI: the active loading of erlotinib.HCl

  2025cites this paper
• Monocyte-adhesive peptidyl liposomes for harnessing monocyte homing to tumor tissues.

  2025cites this paper
• ELABELA-32 Alleviates Doxorubicin-Induced Chronic Cardiotoxicity by Inhibiting the TGF-β/Smad Signaling Pathway

  2025cites this paper
• In Silico and In Vitro Evaluation of Chitosan‐Folate Coated Nanoliposomes Loaded With Cassia alata Leaf Extract for Targeted Breast Cancer Therapy

  2025cites this paper
• Automated High-Content, High-Throughput Spatial Analysis Pipeline for Drug Screening in 3D Tumor Spheroid Inverted Colloidal Crystal Arrays

  2025influential citation
• Liposome‐Enabled Nanomaterials for Muscle Regeneration

  2025cites this paper
• Preparation of Metal-Polyphenol Modified Zeolitic Imidazolate Framework-8 Nanoparticles for Cancer Drug Delivery.

  2025cites this paper
• Doxorubicin-Conjugated Nanoparticles for Potential Use as Drug Delivery Systems

  2025influential citation
• “On-demand” pH triggered drug release system with tunable isoelectric point

  2025cites this paper
• Blackberry-Like Doxorubicin Loaded Hyaluronic Acid/Zinc Phthalocyanine Loaded Mesoporous Silica Nanocomposites for Long-Term Tumor Photodynamic and Chemotherapy Synergistic Therapy

  2025cites this paper
• Engineered RBC-derived nanovesicles functionalized with tumor-targeting ligands: A comparative study on breast cancer targeting efficiency and biocompatibility

  2025cites this paper
• Propolis Extract Reduces Doxorubucin‐Induced Brain Damage by Regulating Inflammation, ER Stress, Oxidative Stress, and Apoptosis

  2025cites this paper
• Fe-Doped Carbon Dots Control the Biodegradation Behaviors of Zr-Based Metal-Organic Framework for Tumor-Specific Chemotherapy and Ferroptosis Enhanced Sono-Chemodynamic Therapy.

  2025cites this paper
• BSA-Coated Copper Ferrite Nanoparticles Loaded with Doxorubicin for Synergistic Ferroptosis-Chemotherapy for Cancer Treatment.

  2025cites this paper
• Impact of Techno-Stress on Employee Productivity & Burnout

  2025cites this paper
• An overview of porphyrin-comprising supramolecular scaffolds for cancer phototherapy

  2025cites this paper
• Development of a novel Cu-Mn hydroxide layered nanosheet-loaded drug modulating the tumour microenvironment and enhancing antitumor effects.

  2025cites this paper
• Engineering HLA-G-targeted extracellular vesicles nanoplatform for enhanced cancer therapy through precise cancer drug delivery

  2025cites this paper
• Elabela Attenuates Doxorubicin-Induced Oxidative DNA Damage and Apoptosis in Rat Left Ventricular Myocardium

  2025cites this paper
• Investigation of the anticancer effects of doxorubicin-loaded niosomes on HCT-116 cells and the expression levels of LncRNAs DLGAP1-AS1 and AFAP1-AS1 in colorectal cancer

  2025cites this paper
• Pathophysiology of Doxorubicin-Mediated Cardiotoxicity

  2025cites this paper
• Hollow mesoporous Prussian blue nanozymes alleviate doxorubicin-induced cardiotoxicity by restraining oxidative stress associated with Nrf2 signaling.

  2025cites this paper
• MXene‐Integrated Composites for Biomedical Applications: Synthesis, Cancer Diagnosis, and Emerging Frontiers

  2025cites this paper
• A heterojunction-engineering nanodrug with tumor microenvironment responsiveness for tumor-specific cuproptosis and chemotherapy amplified sono-immunotherapy.

  2025cites this paper
• Advancements of algae-involved cancer treatment

  2025cites this paper
• Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy

  2025cites this paper
• Fabrication of biodegradable polycaprolactone/chitosan nanoparticle/sodium alginate-based tablet implants for controlled doxorubicin release

  2025cites this paper
• Interaction of doxorubicin with carbon nanotubes in the capillaries surrounding cancer tumors using molecular dynamics simulation: The impact of pH on the thermal properties

  2025cites this paper
• Oligoelectrolyte-mediated, pH-triggered release of hydrophobic drugs from non-responsive micelles: Influence of oligo(2-vinyl pyridine)-loading on drug-loading, release and cytotoxicity.

  2024cites this paper
• Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account

  2024cites this paper
• Cardioprotective effect of chelidonic acid against doxorubicin-induced cardiac toxicity in rats.

  2024cites this paper
• Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma

  2024cites this paper
• Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges

  2024cites this paper
• The Potential of the Fibronectin Inhibitor Arg-Gly-Asp-Ser in the Development of Therapies for Glioblastoma

  2024cites this paper
• Different Doxorubicin Sensitivity Across Various Human Cancer Cell Lines

  2024cites this paper
• Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors.

  2024cites this paper
• Phytotherapeutics in Cancer: From Potential Drug Candidates to Clinical Translation.

  2024cites this paper
• Conjugating Daunorubicin and Doxorubicin to GTP by Formaldehyde to Overcome Drug Resistance

  2024cites this paper
• Herbal compounds as promising therapeutic agents in precision medicine strategies for cancer: A systematic review.

  2024cites this paper
• Ruthenium (Ru) complex conjugates drugs and targeted tumors by inhibiting oral cancer cells

  2024cites this paper
• A Robust Chromatographic Method for Drug Release Profiling of Liposomal Doxorubicin HCl.

  2024cites this paper
• Nanoplatform based on carbon nanoparticles loaded with doxorubicin enhances apoptosis by generating reactive oxygen species for effective cancer therapy

  2024cites this paper
• An NIR-II-photoresponsive CoSnO3 nanozyme for mild photothermally augmented nanocatalytic cancer therapy.

  2024cites this paper
• Biodegradable CoSnO3 nanozymes modulate pH-responsive graphene quantum dot release for synergistic chemo-sonodynamic-nanocatalytic cancer therapy

  2024cites this paper
• A peek under the peak: Spectroscopic investigation of potential charge transfer and hydrogen-bonded complexes of doxorubicin with fullerenol nanoparticles

  2024cites this paper
• Recent advances in polysaccharide-based drug delivery systems for cancer therapy: a comprehensive review

  2024cites this paper
• Impact of formulation parameters and circulation time on PEGylated liposomal doxorubicin related hand-foot syndrome.

  2024cites this paper
• Controlled release of doxorubicin from Poly-(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by coaxial electrospraying.

  2024cites this paper
• Immobilization of doxorubicin on Fe3O4 magnetic nanoparticles modified with iron and silicon glycerolates

  2024cites this paper
• Transferrin-conjugated UiO-66 metal organic frameworks loaded with doxorubicin and indocyanine green: A multimodal nanoplatform for chemo-photothermal-photodynamic approach in cancer management.

  2024cites this paper
• Doxorubicin-loaded liposome-like particles embedded in chitosan/hyaluronic acid-based hydrogels as a controlled drug release model for local treatment of glioblastoma.

  2024cites this paper
• Carrier-Free, Hyaluronic Acid-Modified Self-Assembled Doxorubicin, and Chlorin e6 Nanoparticles Enhance Combined Chemo- and Photodynamic Therapy in vivo

  2024cites this paper
• Theranostic nanoparticles for detection and treatment of pancreatic cancer.

  2024cites this paper
• Advances in exosome research in the management of lung cancer.

  2023cites this paper
• Discovery of C-5 Pyrazole-Substituted Pyrrolopyridine Derivatives as Potent and Selective Inhibitors for Janus Kinase 1.

  2023cites this paper
• Crystalline Nanoparticles of Water-Soluble Covalent Basket Cages (CBCs) for Encapsulation of Anticancer Drugs.

  2023cites this paper
• New Methacrylated Biopolymer-Based Hydrogels as Localized Drug Delivery Systems in Skin Cancer Therapy

  2023cites this paper
• GABA Administration Ameliorates the Toxicity of Doxorubicin on CSF and the Brain of Albino Rats

  2023cites this paper
• Alpha-tocopheryl succinate and doxorubicin-loaded liposomes improve drug uptake and tumor accumulation in a murine breast tumor model

  2023cites this paper
• CD163 Monoclonal Antibody Modified Polymer Prodrug Nanoparticles for Targeting Tumor-Associated Macrophages (TAMs) to Enhance Anti-Tumor Effects

  2023cites this paper
• Advanced biomaterials for human glioblastoma multiforme (GBM) drug delivery.

  2023cites this paper
• Penetrative and Sustained Drug Delivery Using Injectable Hydrogel Nanocomposites for Postsurgical Brain Tumor Treatment.

  2023cites this paper
• Doxorubicin-loaded nanostructured lipid carriers functionalized with folic acid against MCF-7 breast cancer cell line

  2023cites this paper
• Recent advances in nanoscale metal-organic frameworks for cancer chemodynamic therapy.

  2023cites this paper
• Hierarchical superparamagnetic metal-organic framework nanovectors as anti-inflammatory nanomedicines.

  2023cites this paper
• Astragaloside IV Inhibits NLRP3 Inflammasome-Mediated Pyroptosis via Activation of Nrf-2/HO-1 Signaling Pathway and Protects against Doxorubicin-Induced Cardiac Dysfunction.

  2023cites this paper
• Glutathione-Responsive Organosilica Hybrid Nanosystems for Targeted Dual-Starvation Therapy in Luminal Breast Cancer.

  2023cites this paper
• Recent advances and futuristic potentials of nano-tailored doxorubicin for prostate cancer therapy

  2023cites this paper
• Mechanistic insight into loading of doxorubicin hydrochloride onto carbonized FeNPs@ZIF-8 composite

  2023cites this paper
• Biodegradable porous polymeric drug as a drug delivery system: alleviation of doxorubicin-induced cardiotoxicity via passive targeted release

  2023cites this paper
• Doxorubicin Conjugates: An Efficient Approach for Enhanced Therapeutic Efficacy with Reduced Side Effects

  2023cites this paper
• Pectolinarigenin inhibits bladder urothelial carcinoma cell proliferation by regulating DNA damage/autophagy pathways

  2023cites this paper
• Synergistic Effects of Multidrug/Material Combination Deliver System for Anti-mutidrug-resistant Tumor.

  2023cites this paper
• Synergistic approach to combat triple-negative breast cancer: Ti3C2/TiO2-based photothermal combined with sonodynamic process for tumor ablation

  2023cites this paper
• Diosmin alleviates Doxorubicin-induced chemobrain in rats via inhibition of oxido-inflammation, apoptosis and modulation of autophagy

  2023cites this paper
• Recent advances in nanomaterial-based drug delivery systems for melanoma therapy

  2023cites this paper
• In vitro co-delivery of 5-fluorouracil and all-trans retinoic acid by PEGylated liposomes for colorectal cancer treatment

  2023cites this paper
• Optimized DOX Drug Deliveries via Chitosan-Mediated Nanoparticles and Stimuli Responses in Cancer Chemotherapy: A Review

  2023cites this paper
• Gliadin Nanoparticles Containing Doxorubicin Hydrochloride: Characterization and Cytotoxicity

  2023cites this paper
• Co-Encapsulation of Simvastatin and Doxorubicin into pH-Sensitive Liposomes Enhances Antitumoral Activity in Breast Cancer Cell Lines

  2023cites this paper
• Preparation and physicochemical properties of cisplatin and doxorubicin encapsulated by niosome alginate nanocarrier for cancer therapy.

  2023cites this paper
• Reversal of Multidrug Resistance by the Synergistic Effect of Reversan and Hyperthermia to Potentiate the Chemotherapeutic Response of Doxorubicin in Glioblastoma and Glioblastoma Stem Cells.

  2023cites this paper